LeMaitre Vascular (LMAT)
(Real Time Quote from BATS)
$82.29 USD
+0.99 (1.22%)
Updated Jul 5, 2024 11:30 AM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Brokerage Reports
LeMaitre Vascular, Inc. [LMAT]
Reports for Purchase
Showing records 121 - 140 ( 191 total )
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Healthcare - Coverage Update - Healthcare Sector
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
We are placing shares of LMAT Under Review, and transferring coverage to Scott Henry, CFA due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
We are placing shares of LMAT Under Review, and transferring coverage to Scott Henry, CFA due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Biologics Strength, Cost Containment Drive 2Q Beat and Raise
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Light 4Q Offset by Solid 2017 Outlook; Maintain Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Updating Model for Restore Flow Allografts Acquisition
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Record 3Q on Accelerated Sales Growth and Notable Margin Expansion; Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
2Q Beat and Raise; Baxter Disruption is a New Tailwind
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Solid 1Q; ProCol Acquisition Leads to Increased 2016 Growth Outlook
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
ProCol Acquisition - Small but Synergistic Biologic Tuck-In
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
4Q Record Sales, EBITDA, EPS; 2016 Guide Above Expectations; Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C